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Abstract
Collapsing glomerulopathy and microcysts are characteristic histological features of HIV-
associated nephropathy (HIVAN). We have previously reported the role of epithelial 
mesenchymal transition (EMT) in the development of glomerular and tubular cell phenotypes in 
HIVAN. Since persistent tubular cell activation of NFκB has been reported in HIVAN, we now 
hypothesize that HIV may be contributing to tubular cell phenotype via lysophosphatidic acid 
(LPA) mediated downstream signaling. Interestingly, LPA and its receptors have also been 
implicated in the tubular interstitial cell fibrosis (TIF) and cyst formation in autosomal dominant 
polycystic kidney disease (PKD). Primary human proximal tubular cells (HRPTCs) were 
transduced with either empty vector (EV/HRPTCs), HIV (HIV/HRPTCs) or treated with LPA 
(LPA/HRPTC). Immunoelectrophoresis of HIV/HRPTCs and LPA/HRPTCs displayed enhanced 
expression of pro-fibrotic markers: a) fibronectin (2.25 fold), b) connective tissue growth factor 
(CTGF; 4.8 fold), c) α-smooth muscle actin (α-SMA; 12 fold), and d) collagen I (5.7 fold). HIV 
enhanced tubular cell phosphorylation of ILK-1, FAK, PI3K, Akt, ERKs and P38 MAPK. HIV 
increased tubular cell transcriptional binding activity of NF-κB; whereas, a LPA biosynthesis 
inhibitor (AACOCF3), a DAG Kinase inhibitor, a LPA receptor blocker (Ki16425), a NF-κB 
inhibitor (PDTC) and NFkB-siRNA not only displayed down regulation of a NFκB activity but 
also showed attenuated expression of profibrotic/EMT genes in HIV milieu. These findings 
suggest that LPA could be contributing to HIV-induced tubular cell phenotype via NFκB 
activation in HIVAN.
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Introduction
Renal tubular epithelial cell infection and microcyst formation have been reported in HIV 
associated nephropathy (HIVAN). It has been suggested that HIV-1 gene transcript 
increases as tubules dilate and the epithelium becomes flattened and atrophic [1–3]. To date, 
the fate of the segments that become infected by HIV-1 and the ones which develop 
microcysts in HIVAN is not clearly understood. The molecular mechanism by which the 
viral gene expression leads to microcyst formation is far from clear. We have earlier 
demonstrated the role of epithelial mesenchymal transition for proliferative phenotype for 
both glomerular and tubular cells in HIVAN (4, 5).
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Renal fibrosis is characterized by glomerulosclerosis and tubulointerstitial fibrosis (TIF) 
with accumulation of extracellular matrix (collagens and fibronectin) and infiltration of 
macrophages and lymphocytes [3–4, 6]. During the last decade, connective tissue growth 
factor (CTGF) has been implicated to have a dominant role either directly or indirectly in 
mediating tubular cell injury [4–6]. EMT plays a critical role in renal fibrosis. Tightly bound 
epithelial cells get detached following loss of cell polarity and get converted to 
mesenchymal cells expressing mesenchymal proteins and develop migratory potential. In 
kidney and lung, collagen and CTGF are excessively expressed. CTGF is a secreted 
matricellular protein which plays an important role in pathogenesis of chronic fibrotic 
diseases.
Recent reports demonstrate significant involvement of phospholipids in the development of 
fibrosis including platelet activating factor (PAF), phosphatidyl choline, and lysophosphatic 
acid (LPA) [7–8]. Cystic fluid in patients of Polycystic Kidney Disease (PKD) has been 
shown to have increased levels of LPA [9]. LPA seeps to vascular as well as interstitial 
spaces and promotes cyst enlargement. LPA is known to regulate several cellular processes 
including cell motility, proliferation, survival, and differentiation [9–10]. LPA acts via 
specific G-protein coupled receptors (LPA1 to LPA5) [10]. However, the metabolic origin 
of LPA remains to be elucidated. Based on biosynthetic pathways, several enzymes involved 
seem to be activated such as phospholipases A1/A2, lysophospholipase D/autotoxin (ATX), 
glycerol phosphate acyl transferase, or monoacyl glycerol kinase (MAGK)-all leading to 
increased LPA synthesis [11].
In the present study, we have demonstrated that HIV-transduced/LPA treated-HRPTCs 
display an increased expression of molecular markers of profibrotic/EMT phenotype; 
moreover, HIV-and LPA-induced downstream signaling events are ILK-FAK dependent and 
result in NFκB activation and gene transcription.
Methods
Cells and viruses
Human renal proximal tubular cells (HRPTCs) were obtained from ScienCell Research Labs 
(Carlsbad, CA, USA). HRPTCS were cultured using EpiCM medium (ScienCell). Cells 
were maintained at 37°C, 5% CO2 in a humidified incubator. LPA was purchased from 
Avanti Polar Lipids (Alabaster, AL). LPA was prepared in PBS containing 0.1% BSA (vol/
vol) and sonicated before use. HRPTCS, Control (C/HRPTCs) and Empty vector (EV/
HRPTC) or treated with HIV/LPA [(HIV/HRPTC)/LPA/HRPTCs) wherever indicated were 
used in the study.
Production of pseudotyped retroviral supernatant
Replication-defective viral supernatants were prepared as published previously [3]. Briefly, 
green fluorescence protein (GFP) reporter gene (from pEGFP-C1; Clontech, Palo Alto, CA) 
was substituted in place of gag/pol genes in HIV-1 proviral construct pNL4-3. This parental 
construct (pNL4-3: ΔG/P-GFP) was used to produce VSV.G pseudotyped viruses to provide 
pleiotropism and high-titer virus stocks. Infectious viral supernatants were produced by the 
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transient transfection of 293T cells using effectene (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. The HIV-1 gag/pol and VSV.G envelope genes were provided 
in trans using pCMV R8.91 and pMD.G plasmids,(gifts by Dr. Didier Trono, Salk Institute, 
La Jolla, CA). Viral stocks ranging from 105 to 106 GEU/ml were obtained.
Transfection
HRPTCs were transfected using lipofectamine plus reagent according to the manufacturer’s 
protocol with a total of 1 μg/well of plasmid DNA. Twenty-four hours later, the cells were 
treated with HIV or LPA (24 hr), followed by further incubation at 37°C. For NFκB-
luciferase activity, HRPTCs were transfected with NFκB-luciferase reporter plasmid and/or 
using p65 DN plasmid with pCMV-β-gal by Lipofectamine Plus. pcDNA3 was used to 
normalize all groups to equal amounts of DNA Luciferase (Promega, Madison, WI) further 
normalizing with β-galactosidase activity. NFκB-luciferase, DN-p65 plasmids were kindly 
provided by Dr. George Rawadi (Institute Pasteur, Laboratoire des Mycoplasmes, Paris, 
France) (12). The expression vector for flag-IKKα was a gift from Dr Zheng-Gang Liu 
(National Institutes of Health, Bethesda, MD).
Silencing of NFκB—HRPTCs were transfected with 25–50 nM NFκB small interfering 
(Si) RNA (Santa-Cruz Biotechnology; Santa Cruz, CA) with Siport Neofax transfection 
reagent and left in optiMEM medium for 24 –48h and the cells were transferred back to 
HRPTC medium an hour before transfection with NL4-3 GFP.
Immunodetection by Western blot
HRPTCs, HIV/HRPTCs, and EV/HRPTCs were incubated in medium for 3 days. Cells were 
lysed in RIPA buffer containing 50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 
1% NP-40, 0.25% deoxycholate, 0.1% SDS, 1× protease inhibitor cocktail I (Calbiochem, 
EMD Biosciences, Gibbstan, NJ), 1 mM PMSF, and 0.2 mM sodium orthovanadate. Protein 
concentration was determined using the Biorad Protein Assay (Pierce, Rockford, IL). 
Protein lysates (20 μg) were separated on 12% polyacrylamide gels (PAGE, Bio-Rad, 
Hercules, CA) and transferred onto a nitrocellulose membrane using Bio-Rad miniblot 
apparatus. Nitrocellulose membranes were then subjected to immunostaining with primary 
antibodies against CTGF, TGF–β, fibronectin, vimentin, α-SMA and SNAIL (Santa Cruz 
Biotechnology, Dallas, TX, USA), NFκB pathway proteins (phosphospecific, Cell 
Signaling, Danvers, MA), p-ILK1, and p-FAK (EMD Millipore, Billerica, MA, USA), and 
subsequently with horseradish peroxidase-labeled appropriate secondary antibodies (Biorad, 
Hercules, CA). The blots were developed using a chemiluminescence detection kit 
(ThermoScientific, Rockford, IL, USA) and exposed to X-ray film (Eastman Kodak, 
Rochester, NY). Equal protein loading was confirmed by stripping and reprobed the same 
blots immunoblotting for β–actin protein. For quantification, the immunoblots were scanned, 
and densitometry was performed by Image J analysis; values were normalized to β–actin 
expression and expressed as fold increase when compared to control values as shown.
Preparation of nuclear extracts and electrophoretic mobility shift assay (EMSA)
Nuclear extracts from control and experimental cells (1 × 107) were prepared as described 
previously [12–14]. Aliquots (1μg) were used for the electrophoretic mobility shift assay 
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using the NFκB DNA-binding protein detection system kit (Affymetrix). Briefly, the 
protein-binding biotinylated DNA probes (NFκB) were incubated with nuclear extracts 
prepared from control and experimental cells according to the manufacturer’s protocol 
(Panomics, Redwood City, CA). The DNA-protein binding reactions were performed at 
room temperature for 10 min in 10 mM Tris-Hcl pH 7.9, 50 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA, and 1 mM dithiothreitol plus 1 μg of poly (dI-dC), 5% (v/v) glycerol, and ~10 ng of 
biotinylated NFκB probe. Protein DNA complexes were resolved from protein-free DNA on 
6 % polyacrylamide gels (Invitrogen) at 4° C in 50 mM Tris, pH 8.3, 2 mM EDTA. DNA-
protein complexes and rest of the gel contents were transferred to Biodyne B membrane 
(Pall, Ann Arbor, MI) for 60 min at 300 mA. The membranes now containing the DNA-
protein complexes were UV cross linked and chemiluminescent detection of biotinylated 
DNA was performed using the Panomics EMSA kit.
Results
HIV/HRPTCs and LPA/HRPTCs show higher expression of fibronectin, CTGF, collagen I, α-
SMA, and vimentin
HIV expressing tubular cells and LPA-treated tubular cells displayed similar molecular 
phenotype (Fig. 1A). LPA inhibitors and a LPA receptor inhibitor (Ki16425) attenuated the 
expression of profibrotic/EMT molecular markers. HIV enhanced tubular cell fibronectin by 
an average 2.3 (50–100 U) fold, whereas LPA enhanced tubular cell fibronectin expression 
by an average 1.7 (1 μM–5μM) fold. Similarly, HIV enhanced tubular CTGF expression by 
an average 4.85 fold and LPA increased tubular cell expression of CTGF by an average 5.15 
fold at two different concentrations. HIV increased tubular cell collagen-I expression by an 
average of 5.95 fold and LPA enhanced collagen-I expression by an average 5.75 fold. HIV 
enhanced tubular cell α-SMA expression by an average 12 fold and LPA enhanced tubular 
cell expression of α–SMA by an average 5.9 fold. Similarly, both HIV and LPA enhanced 
tubular cell expression of vimentin 1.85 and 1.6 folds at two different concentrations, 
respectively (Fig 1.B). HRPTCs were preincubated with either a LPA receptor blocker 
(Ki16425 1, 10 μM), a PLA2 inhibitor, AAOCOCF3 (1 and 10 μM), or a DAG kinase 
inhibitor (50, 150 nM) for 4 h prior to treatment with HIV or with LPA. After 72h, cells 
were harvested and protein blots were probed for fibronectin, collagen I, vimentin, α-SMA, 
SNAIL, and CTGF. HIV and LPA enhanced tubular cell expression of fibronectin, collagen 
I, α-SMA, SNAIL or CTGF by several fold (Fig. 2A) On the other hand, a LPA synthesis 
blockers and a LPA receptor inhibitor overtly attenuated the expression of fibronectin, α-
SMA, SNAIL and CTGF (Approx 80%); however, decrease in tubular cell expression of 
collagen I and vimentin was quite modest in response to LPA inhibitors.
Both LPA and HIV enhanced tubular cell expression of p-ILK-1, p-FAK, p-PI3K, p-Akt, and 
pP38 MAPK, p-ERK, leading to p65 phosphorylation (NFκB)
Several reports show the involvement of Integrin Linked Kinase (ILK), Focal Adhesion 
Kinase (FAK) pathways leading to the NFκB activation [16]. The activation of ILK-1/FAK 
pathways has also been associated with EMT [17–18]. Immunoblots from LPA/HIV 
stimulated HRPTCs displayed enhanced expression of p-ILK, p-FAK, p-PI3K, p-p38, ERK, 
p-AKT ranging from 5 to 10 fold (Fig. 3). We observed several fold increases in the 
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phosphorylation status of these upstream kinases (ILK, FAK as well PI3K) by 6h while the 
downstream kinases displayed further persistent activation up to 3 days (p-Akt, ERK as well 
p-p38) (Fig. 3). We observed similar increases (5–10 fold) in the phosphorylated status of 
p65 (the NFκB component) by day 1 and persistent increased levels up to day 5. HIV/
HRPTCs or LPA/HRPTCs showed significant increases in the activation of both upstream 
as well downstream kinases leading to NFκB activation (as shown in p-p65 phosphorylation 
status) and in the expression of the profibrotic/EMT genes such as fibronectin, CTGF, 
collagen-I, α–SMA and vimentin.
HIV enhanced transcriptional binding activity of NF-κB
Lysates from HIV/HRPTCs (Fig. 3) were probed for molecular markers of canonical NFκB 
pathway. According to current understanding, activation and phosphorylation of p65 
involves activation of upstream IKK α/β/γ complex of proteins by upstream regulators often 
leading to phosphorylation of α/β subunits of the IKK complex, which subsequently 
phosphorylates the IκBα –bound to p65-p50 subunit complex [12, 19–20]. Phosphorylation 
of IκB complex enables to dissociate itself from p-65-p50 subunits, which otherwise are 
sequestered in the cytoplasm bound to IκB-α. Detached p65-p50 subunit complex now 
migrates to the nucleus and then binds to κB (kappa B) elements of the promoter regions of 
the transcribed genes. Phosphorylated p65 (p-p65), is an indication of transcriptionally 
active NFκB complex. Immunoblot analysis of the lysates from HIV treated cells, 
demonstrated an increase in Ikk-α/β phosphorylation and upregulation of IκB-α 
phosphorylation, thus leading to p-p65 phosphorylation (results not shown).
Persistent NF-κB activation in renal epithelial cells has been reported in a mouse model of 
HIVAN [21]; however, the role of either HIV or LPA leading to the activation of 
profibrotic/EMT molecules involving the activation of NFκB pathways in HIVAN has not 
been examined so far. We studied the effect of these various inhibitors of the LPA 
biosynthesis pathways (see Fig. 2A) on NFκB activation via EMSA (Fig. 4). Both HIV and 
LPA increased the NFκB binding activity in HIV/HRPTCs [Fig. 4A]. We had earlier 
reported sphingomyelinase (generation of ceramide) is redox sensitive and vice versa [14] 
and in conjunction with studies more recently that, HIV induced altered cellular redox [3], 
treatment of HRPTCs with either sphingomyelinase or with hydrogen peroxide led to a 
robust activation of NFκB binding activity. Interestingly pretreatment with various 
inhibitors, both LPA blockers and a LPA receptor inhibitor (Ki16425) reduced NFκB 
binding activity in HRPTCs [Fig. 4A]. This activation of NFκB was also blocked by PDTC 
(an antioxidant as well as NFκB blocker). To confirm the involvement of the canonical 
NFκB pathway by p65 Rel A, we examined the effect of PDTC, and a p65 DN construct on 
NFκB reporter activity (Fig. 4B). HRPTCs were transiently transfected with NFκB-
luciferase followed by treatment with or without PDTC in HIV milieu. After 4 h, the cell 
lysates were processed for luciferase activity. PDTC significantly inhibited the HIV induced 
NFκB Luciferase activity in transfected HRPTCs. Control cells showed minimal basal 
activity. Further cells co-transfected with an expression vector of IKK-α, along with NFκB 
luciferase reporter, were treated with HIV/PDTC. Luciferase activity in cells transiently 
expressing IKK α was further increased in comparison to control NFκB reporter activity in 
HRPTCs, suggesting that LPA acts upstream of IKKα in the NFκB pathway. The inhibitory 
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effect of PDTC in NFκB luciferase reporter activity in HRPTC is due to its effect on NFκB 
pathway as well as in part could be due to the down regulation of upstream events mainly by 
reducing an increase in altered cellular redox. Finally, in order to test if blocking NFκB 
related events can result in down regulation of elevated gene expression, HRPTCs were 
transfected with p65 NFκB siRNA or treated with PDTC, before stimulation with HIV (Fig. 
4C). Results showed reduced expression of TGF-β, CTGF, fibronectin, and collagen-I, α-
SMA and SNAIL. p65 siRNA/HRPTCs also displayed reduced expression of p65 (NFκB). 
[Fig. 4]. These results confirm that NFκB either directly or indirectly regulates HIV induced 
altered gene expression in HRPTCs.
Discussion
The present study demonstrates involvement of LPA in HIV mediated up regulation of 
profibrotic/EMT markers. We delineated the mechanisms involved in HIV activated and 
LPA mediated EMT/profibrotic gene expression in the involvement of FAK/ILK pathways 
and PI-3 kinase, ERK, Pkb/Akt activation of canonical NF-κB pathway. Several 
experimental studies support the hypothesis that HIV induces upregulation of these various 
profibrotic/EMT mediators via LPA as well NFκB activation. First, by use of LPA 
biosynthetic pathway inhibitors and LPA receptor blockers. Second, by inhibition of NFκB 
activity by using a NFκB blocker (PDTC) as well as silencing of NFκB in tubular cells; both 
the interventions reduced the LPA/HIV-induced downstream signaling, and expression of 
profibrotic mediators (Fig. 5). These findings indicate that HIV and LPA activate several 
common signaling intermediary molecules (FAK/ILK pathway involving Pkb/Akt, PI-3 
kinase, ERK and p38 kinases) leading to the activation of FAK/ILK and canonical NFκB 
pathways. Our current study highlights a crucial regulatory role of the NFκB, demonstrating 
1) enhanced binding activity of NFκB by either HIV or LPA treatment of HRPTCs, 2) 
reduction of NFκB binding activity by LPA synthesis blockers and LPA receptor inhibitors, 
3) down regulation of profibrotic/EMT gene expression by LPA synthesis blockers and LPA 
receptor inhibitors, 4) participation of various signaling intermediates such as FAK/ILK 
involving activation of downstream signaling molecules such as PI-3 K, Pkb/Akt, ERK, and 
p38 kinase, 5) reduction in NFκB binding by cell signaling inhibitors, 6) reduction in the 
expression of tubular cell profibrotic protein markers by NFκB inhibitor (PDTC) and 
silencing of NFκB and 7) enhanced expression of NFκB Luciferase activity, that can be 
significantly reduced by PDTC, and co-expression of dominant negative –p65 (DN-p65). All 
these observations suggest the participation of canonical NFκB pathway which was 
confirmed by demonstration that over expression of IKKα causes significant increases in 
NFκB Luc activity; however, this was effectively reduced in cells pretreated with PDTC or 
by co-expressing DN-P65. Our findings support the hypothesis that a) LPA plays a critical 
role in HIV mediated profibrotic and EMT events which may be contributing to microcyst 
formation in HIV milieu, b) HIV through LPA is involved in signaling events that activate 
FAK/ILK, PI-3-Kinase, Pkb/Akt, ERK, p38 kinases and involvement of canonical NFκB 
activation cascades thereby leading to the enhanced transcription of these profibrotic 
proteins. Several recent reports suggest a cross talk between TGF-β pathways leading to an 
increase in ILK-1 activity and induction of EMT [17]. Although the current emphasis and 
focus is on TGF-β lead pathways, the present study demonstrates that HIV/LPA mediates 
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their effects via LPA receptor stimulated mechanisms which may or may not have a 
crosstalk with TGFβ stimulated pathways. It reflects degeneracy in mechanisms related to 
growth and survival. CTGF stimulated pathways may function downstream or in parallel to 
TGF-β led pathways in leading the cells towards loss of their phenotype [22]. Several recent 
reports suggest a cross talk between TGF-β pathways leading to an increase in ILK-1 
activity and an induction of EMT [17]. Focal adhesion kinase (FAK a downstream ILK 
linked signal transducer) yet another important molecule has also been associated with TGF-
β-induced renal tubular EMT [18]. Overexpression of ILK correlated to aberrant expression 
in EMT markers such as SNAIL, in oral squamous cell carcinoma [23]. ILK has been 
implicated in high glucose-induced renal tubular cell injury [24]. Small interfering RNA 
targets ILK inhibited cancer metastasis [25]. Thus, ILK seems to be a key molecule in EMT 
and tubular cell injury.
Peptide mediators PDGF–β as well CTGF activate kidney pericytes and fibroblasts causing 
proliferation, collagen synthesis and fibrosis (26). These peptides are produced in abundance 
by tubules when they regenerate during reperfusion and ischemic injury. And unlike the 
normal proximal tubules, these tubular cells without differentiated features seem to express 
vimentin, an intermediary filament protein expressed by surviving cells as they 
dedifferentiate and proliferate after injury.
In summary, we have shown that both LPA and HIV lead tubular cells to express proteins 
related to pro-proliferative phenotype including SNAIL and vimentin. Several other reports 
suggest that promoter of NFκB site may act as a positive regulatory element for the 
transcription of vimentin [21–22]. Interestingly, NF-κB suppresses the expression of E-
cadherin and desmoplakin and induces the expression of vimentin [27–28]. Similarly, 
together with Snail1, the p65 subunit of NF-κB enhances fibronectin gene 29–30].
We conclude that HIV promotes tubular cell expression of EMT/profibrotic markers via 
LPA, and by upregulation of FAK/ILK, PI-3 kinase cascades involving Akt, p38 and ERK 
kinases, and thereby causing an activation of canonical NFκB pathway.
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• HIV and LPA treated tubular cells displayed profibrotic/EMT molecular 
phenotype
• HIV and LPA treated tubular cells showed phosphorylation of ILK-1, FAK, 
PI3K, Akt, ERKs and P38 MAPK
• HIV and LPA treated tubular cells displayed activation of NF-kB
• LPA blockers, kinase inhibitors, siRNA of NF-kB inhibited these tubular cell 
effects of HIV and LPA
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A. HIV/LPA induced upregulation of EMT/fibrosis markers fibronectin, Connective Tissue 
Growth factor (CTGF), Collagen I, α-SMA and Vimentin HRPTCS were treated with 
HIV/LPA for 72 h followed by cell lysate preparation and immunoblot analysis together 
with Control (CN) and Empty vector (EV). Quantified protein bands reported here as fold 
change, was calculated by densitometry with normalization to βactin expression and are 
shown in the Table (B).
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LPA synthesis blockers (AACOCF3 and DAG kinase inhibitor) as well LPAR inhibitor 
(Ki16425) attenuated HIV/LPA- induced EMT/profibrotic gene expression. Cellular lysates 
were prepared following pretreatment in the presence or absence of inhibitors Protein blots 
showing the expression of various profibrotic proteins are displayed.
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A and C. Cell lysates were prepared following the indicated treatment, in the presence of 
phosphatase inhibitors. Immunoblots were prepared from the cell lysates. Protein level 
expression at various time points are shown. Fold increases in phospho-protein expression, 
normalized to actin expression, are represented as a curve graph (B and D).
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Fig. 4. Both HIV and LPA induced higher binding activity of NFκB
A. Nuclei from HRPTCs were extracted following various treatments (as indicated) and 
EMSA was performed. HIV or LPA added in indicated concentrations. Sphingomyelinase 
(SMase) 100 mUnits/ml or Hydrogen peroxide (HP-0.5 mM) were loaded in lanes 8 and 10 
respectively. Use of cold unlabeled probe, in the binding assay, suggests the specific binding 
activity of the fluorescent probe. Treatment with LPA synthesis blockers (as indicated) 
followed by HIV treatment, reduces NFκB binding activity. Lane 10 depicts addition of cold 
oligomer to the reaction mix, 10 min prior to adding labeled fluorescent probe
C. PDTC (50 μM) and DN NFκB inhibit tubular cell NFκB-Luciferase in HIV milieu. 
HRPTCs were transiently transfected with either NFκB-luciferase construct (0.5 μg/well, 
CMV-β-gal (0.5 μg/well), 0.5 μg/well DN-p65, or with IKK-α. After overnight incubation, 
the transfected cells were treated with PDTC for 4h before transducing cells with HIV for 
4h. Cells were lysed and processed for luciferase and β-gal activities. Luciferase activity was 
normalized with respect to β-gal activity and expressed relative to activity of the control. 
Data are mean SD of of three different experimental values.
*P< 0.005 compared to relative control and # P< 0.001 compared with HIV treatment alone.
D. PDTC(+ 25 μM, ++ 50 μM) as well as NFκB siRNA inhibited HIV-induced expression 
of TGF-β, CTGF, Fibronectin, Collagen-1, α–SMA and SNAIL.
HRPTCs were pre-incubated with PDTC (25 or 50 μM) or transfected with NFκB siRNA 
prior to stimulation with HIV and were incubated for 72h. Cellular lysates were prepared 
and protein blots were probed for different protein expression.
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Schematic diagram showing HIV induced alteration in biological membrane leading to LPA 
biosynthesis, and activating various kinase cascade and to NFκB activation and EMT related 
gene modulation. Inhibitors that block LPA pathway, signal transduction process and or 
NFκB activation could effectively block this pathway of EMT gene expression/modulation.
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